Cargando…

Pharmacological Tie2 activation in kidney transplantation

AIM: To investigate the therapeutic potential of vasculotide (VT) - a Tie2 activating therapeutic - in kidney transplantation. METHODS: We performed a murine MHC-mismatched renal transplant model (C57Bl/6 male into Balb/c female) with 60 min cold and 30 min warm ischemia time. 500 ng VT was administ...

Descripción completa

Detalles Bibliográficos
Autores principales: Thamm, Kristina, Njau, Florence, Van Slyke, Paul, Dumont, Daniel J, Park, Joon-Keun, Haller, Hermann, David, Sascha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036127/
https://www.ncbi.nlm.nih.gov/pubmed/27683636
http://dx.doi.org/10.5500/wjt.v6.i3.573
_version_ 1782455501652492288
author Thamm, Kristina
Njau, Florence
Van Slyke, Paul
Dumont, Daniel J
Park, Joon-Keun
Haller, Hermann
David, Sascha
author_facet Thamm, Kristina
Njau, Florence
Van Slyke, Paul
Dumont, Daniel J
Park, Joon-Keun
Haller, Hermann
David, Sascha
author_sort Thamm, Kristina
collection PubMed
description AIM: To investigate the therapeutic potential of vasculotide (VT) - a Tie2 activating therapeutic - in kidney transplantation. METHODS: We performed a murine MHC-mismatched renal transplant model (C57Bl/6 male into Balb/c female) with 60 min cold and 30 min warm ischemia time. 500 ng VT was administered i.p. to donor mice 1 h before organ removal. In addition, recipients received 500 ng VT i.p. directly and 3 d after surgery. Survival was monitored and remaining animals were sacrificed 28 d after transplantation. In this model, we analyzed: (1) organ function; (2) Kaplan-Meier survival; (3) organ damage (periodic acid Schiff staining) via semi-quantitative scoring [0-4 (0 = no injury/inflammation to 4 = very severe injury/inflammation)]; (4) expression of renal endothelial adhesion molecules (ICAM-1) via immunofluorescence (IF) staining, immunoblotting and qPCR; (5) infiltration of inflammatory cells (IF Gr-1, F4/80); and (6) fibrosis via staining of α-smooth muscle actin (αSMA), Sirius red staining and immunoblotting of SMAD3 activation. RESULTS: Exogenous activation of Tie2 with VT resulted in diminished expression of peritubular and glomerular endothelial adhesion molecules. Consequently, infiltration of inflammatory cells (analyzed as ICAM-1, Gr-1 and F4/80 positive cells) was reduced in VT-treated mice compared to controls. Additionally, VT was protective against fibrogenesis after kidney transplantation. Trends towards lower serum creatinine (vehicle: 142 ± 17 μmol/L vs VT: 94 ± 23 μmol/L), urea (vehicle: 76 ± 5 mmol/L vs VT: 60 ± 8 mmol/L) and lactate dehydrogenase (vehicle: 1288 ± 383 iU vs VT: 870 ± 275 iU) were observed on day 6 after transplantation. Kaplan-Meier survival analysis showed improved survival rates in the VT-treated mice that did not reach statistical significance (27% vs 54%, P = 0.24, n = 11 per group). Exogenous activation of Tie2 via VT might reduce infiltration of inflammatory cells into renal tissue thereby protecting the transplant from early graft dysfunction potentially affecting long-term function. CONCLUSION: Protection of the endothelial microvasculature via the Tie2 axis in the early transplant setting might hold promise as a therapeutic target.
format Online
Article
Text
id pubmed-5036127
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-50361272016-09-28 Pharmacological Tie2 activation in kidney transplantation Thamm, Kristina Njau, Florence Van Slyke, Paul Dumont, Daniel J Park, Joon-Keun Haller, Hermann David, Sascha World J Transplant Basic Study AIM: To investigate the therapeutic potential of vasculotide (VT) - a Tie2 activating therapeutic - in kidney transplantation. METHODS: We performed a murine MHC-mismatched renal transplant model (C57Bl/6 male into Balb/c female) with 60 min cold and 30 min warm ischemia time. 500 ng VT was administered i.p. to donor mice 1 h before organ removal. In addition, recipients received 500 ng VT i.p. directly and 3 d after surgery. Survival was monitored and remaining animals were sacrificed 28 d after transplantation. In this model, we analyzed: (1) organ function; (2) Kaplan-Meier survival; (3) organ damage (periodic acid Schiff staining) via semi-quantitative scoring [0-4 (0 = no injury/inflammation to 4 = very severe injury/inflammation)]; (4) expression of renal endothelial adhesion molecules (ICAM-1) via immunofluorescence (IF) staining, immunoblotting and qPCR; (5) infiltration of inflammatory cells (IF Gr-1, F4/80); and (6) fibrosis via staining of α-smooth muscle actin (αSMA), Sirius red staining and immunoblotting of SMAD3 activation. RESULTS: Exogenous activation of Tie2 with VT resulted in diminished expression of peritubular and glomerular endothelial adhesion molecules. Consequently, infiltration of inflammatory cells (analyzed as ICAM-1, Gr-1 and F4/80 positive cells) was reduced in VT-treated mice compared to controls. Additionally, VT was protective against fibrogenesis after kidney transplantation. Trends towards lower serum creatinine (vehicle: 142 ± 17 μmol/L vs VT: 94 ± 23 μmol/L), urea (vehicle: 76 ± 5 mmol/L vs VT: 60 ± 8 mmol/L) and lactate dehydrogenase (vehicle: 1288 ± 383 iU vs VT: 870 ± 275 iU) were observed on day 6 after transplantation. Kaplan-Meier survival analysis showed improved survival rates in the VT-treated mice that did not reach statistical significance (27% vs 54%, P = 0.24, n = 11 per group). Exogenous activation of Tie2 via VT might reduce infiltration of inflammatory cells into renal tissue thereby protecting the transplant from early graft dysfunction potentially affecting long-term function. CONCLUSION: Protection of the endothelial microvasculature via the Tie2 axis in the early transplant setting might hold promise as a therapeutic target. Baishideng Publishing Group Inc 2016-09-24 2016-09-24 /pmc/articles/PMC5036127/ /pubmed/27683636 http://dx.doi.org/10.5500/wjt.v6.i3.573 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Basic Study
Thamm, Kristina
Njau, Florence
Van Slyke, Paul
Dumont, Daniel J
Park, Joon-Keun
Haller, Hermann
David, Sascha
Pharmacological Tie2 activation in kidney transplantation
title Pharmacological Tie2 activation in kidney transplantation
title_full Pharmacological Tie2 activation in kidney transplantation
title_fullStr Pharmacological Tie2 activation in kidney transplantation
title_full_unstemmed Pharmacological Tie2 activation in kidney transplantation
title_short Pharmacological Tie2 activation in kidney transplantation
title_sort pharmacological tie2 activation in kidney transplantation
topic Basic Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036127/
https://www.ncbi.nlm.nih.gov/pubmed/27683636
http://dx.doi.org/10.5500/wjt.v6.i3.573
work_keys_str_mv AT thammkristina pharmacologicaltie2activationinkidneytransplantation
AT njauflorence pharmacologicaltie2activationinkidneytransplantation
AT vanslykepaul pharmacologicaltie2activationinkidneytransplantation
AT dumontdanielj pharmacologicaltie2activationinkidneytransplantation
AT parkjoonkeun pharmacologicaltie2activationinkidneytransplantation
AT hallerhermann pharmacologicaltie2activationinkidneytransplantation
AT davidsascha pharmacologicaltie2activationinkidneytransplantation